Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Venetoclax with azacitidine in HR-MDS

Andrew Wei • 10 Dec 2019
ASH 2019
Myelodysplastic Syndromes Azacitidine Venetoclax

Andrew Wei, MBBS, PhD, Alfred Hospital and Monash University, Melbourne, Australia, covers the phase 1b trial (NCT02942290) of venetoclax in combination with azacitidine in treatment-naïve patients with higher-risk myelodysplastic syndrome (MDS). This revealed a tolerable safety profile and promising efficacy. This interview was recorded at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Andrew Wei

TP53 mutation in AML
Andrew Wei et al. • 4 Sep 2023
6:41
Clinical trials aiming to reduce the toxicity of novel agents in AML
Andrew Wei • 9 Dec 2022
6:14
Oral azacitidine maintenance in AML: QUAZAR AML-001 results after 52 months of follow-up
Andrew Wei • 15 Dec 2021
1:32
AML data at ASH 2021 and implications on clinical practice
Andrew Wei • 15 Dec 2021

Related Videos

2:22
Haplo-SCT for older patients with AML/MDS, and should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals